ClinicalTrials.gg
Not yet recruitingNCT07494292PASSUpdated Aug 6, 2026

Personalised Active Self-management of Sleep Apnea Program

An interventional study of 4-month Personalized and Adaptive Sleep Support program (PASS) and Control group in Obstructive Sleep Apnea (OSA), sponsored by Hong Kong Metropolitan University. Not yet recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Hong Kong Metropolitan University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is to assess the feasibility and acceptability of the PASS in patients with OSA. Second, the study examines its effectiveness in improving PAP uptake and adherence, self-efficacy in self-care, changes in health-related habits, and health outcomes. We also assess the facilitators and barriers to implementing the PASS.

This is a two-group pilot randomized controlled trial (n=60) with a 4-month follow-up. Subjects assigned to the intervention group will receive a 4-month Personalized and Adaptive Sleep Support (PASS) program, a digital platform-based intervention. The 4-month program incorporates: i) a 20-minute brief motivational interviewing session; ii) a digital platform where users can view personalized OSA health-related videos and information, track their adherence to prescribed treatments, log their daily activities and dietary intake, and set personal health goals; and iii) continuous personalized chat-based messaging and phone call support. Participants in the control group will receive a 4-month general hygiene program, including (i) a 20-minute session, (ii) messaging, and (iii) phone call support.

The feasibility and acceptability of the PASS will be evaluated via semi-structured interviews at the 4-month follow-up. Self-administered questionnaires will be used at baseline and 4 months, and objective assessment tools (such as sleep tests) will be used at baseline and at the 4-month follow-ups. PAP adherence data will be downloaded from PAP machines (if available) for all subjects in both groups at baseline and at month 4.

Read the detailed description

This is a two-group pilot randomised control trial with a 4-month follow-up. Forty subjects (30 for the intervention group and 30 for the control group) will be recruited Subject. Subjects in intervention group will receive a 4-month Personalized and Adaptive Sleep Support Program (PASS), a digital platform-based intervention guided by social cognitive theory and use brief motivational interviewing (brief MI) to enhance subjects' psychological capacity and motivation, feel confident in managing chronic situations, and provide continuous individual support. The PASS is a 4-month program utilizing a multimodal approach with three main components: i) A 20-Minute Brief Motivational Interviewing Session, ii) a digital platform, and iii) a continuous personalized chat-based messaging and phone call support. The 20-minute interviewing session utilizes Motivational Interviewing (MI) techniques to engage and motivate participants in managing their OSA. The digital platform providing multiple functions for OSA subjects, including self-selection of personalised OSA health-related videos and information, tracking Positive airway pressure treatment adherence, physical activity levels, diet, sleep habits, body weight, blood pressure, and setting personal health goals. The continuous personalized chat-based messaging and phone call support provides ongoing, tailored support and encouragement through messaging, helping to engage and adhere to the program. Participants receive additional support through regular phone calls, offering a more personal touch and the opportunity to address any specific concerns or challenges they may be facing. Participants in control group will receive a 4-month general hygiene program, including (i) A 20-minute session, (ii) messaging, and (iii) phone call support.

Program feasibility and acceptability will be evaluated via semi-structured interviews at 4 months, while primary outcomes (PAP uptake) and secondary outcomes (including PAP adherence, self-efficacy, health-related habits, and quality of life) will be measured using a combination of self-administered questionnaires (e.g., SEMSA, ESS, ISI), objective activity trackers, and data retrieved from PAP machines at baseline and 4 months, with clinical outcomes like BMI and OSA severity assessed at baseline and the 4-month follow-up.

Self-administered questionnaires will be used at baseline and 4 months, and objective assessment tools (such as sleep tests) will be used at baseline and 4-month follow-up. PAP adherence will be downloaded from PAP machines (if available) for all subjects in both groups at baseline and month 4.

Individual interviews will be conducted after a 4-month program. The aims are to (i) explore subjects' perception and satisfaction with the programme, (ii) understand the impacts and extent to which the changes have sustained and integrated into their daily life; and (iii) identify elements of the programme they view as helpful/unhelpful in supporting them to increase self-management ability, (iv) explore the facilitators and barriers for exercise adherence. If subjects withdraw from the assessment or drop out of the programme, they will not be asked for the reasons, and it will not affect the current treatment and follow-up.

02

Conditions studied

  • Obstructive Sleep Apnea (OSA)

Keywords

  • self-management
  • OSA
  • digital health
03

In context

Sleep Apnea, Obstructive

2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

This study's planned enrollment of 60 is above the median of 52 across 1,472 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

Hong Kong Metropolitan University is the lead sponsor of 56 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years and above
  • Newly diagnosed with OSA (diagnosis made within the past year)
  • Newly started or not yet started Positive Airway Pressure (PAP) treatment, with a treatment duration of less than 6 months
  • Physically inactive (self-reported moderate physical activity per week of \<150 minutes)
  • Overweight (≥23 kg/m2)
  • Mentally, cognitively, and physically fit to join the trial as determined by the doctor in charge and responsible clinical investigators
  • Able to speak, read, and write Chinese
  • Willing to complete the questionnaires and assessments
  • Has a smartphone

Exclusion criteria

Exclusion Criteria:

  • psychiatric disorder
  • Use of prescription drugs or clinically significant drugs affecting sleep.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    General Hygiene Control group

    Participants will receive a 4-month general hygiene information.

    Behavioral: Control group

  • Experimental
    PASS Intervention group

    Subjects in this arm will receive a 4-month digital Personalized and Adaptive Sleep Support program (PASS).

    Behavioral: 4-month Personalized and Adaptive Sleep Support program (PASS)

Interventions

  • Behavioral4-month Personalized and Adaptive Sleep Support program (PASS)

    The 4-month Personalized and Adaptive Sleep Support (PASS) program incorporate 3 components: i) 20-minute brief motivational interviewing Session motivating participants, ii) digital platformThe digital platform enabling participants to access tailored health content, track PAP therapy adherence, log physical data such as activity and diet, and utilize integrated tools for self-monitoring and goal setting, iii) continuous personalized support offering chat-based messaging to promote program engagement and adherence.

  • BehavioralControl group

    Participants will receive a 4-month general hygiene program, including (i) A 20-minute session, (ii) messaging, and (iii) phone call support. The content focuses on hand hygiene and food hygiene

06

What researchers measure

Primary outcomes

  1. Positive airway pressure (PAP) therapy uptake

    Whether the patient start to use the PAP therapy. Answer option: Yes or No

    Time frame: Baseline and 4 months

  2. Program feasibility and acceptability

    Evaluated via semi-structured interviews

    Time frame: 4 months

Secondary outcomes

  1. Positive airway pressure therapy adherence - Intention to use

    The percentage of days on which CPAP has been switched on (ie, total number of switch-on days divided by the total number of study days). Scores ranged from 0% to 100%. The high scores denote the better PAP use.

    Time frame: Baseline and 4 months

  2. Positive airway pressure therapy adherence - mean daily usage

    The total number of hours of mask on divided by the total number of study days, which was downloaded with software. Scores ranged from 0 to 24 hours. The high scores denote the better PAP use.

    Time frame: Baseline and 4 months

  3. Positive airway pressure therapy adherence - Usage Index

    The percentage of days using PAP for at least 4 h/d (ie, total number of such PAP days divided by the total number of study days). Scores ranged from 0% to 100%. The high scores denote the better PAP use.

    Time frame: Baseline and 4 months

  4. Self-efficacy in self-management and treatment adherence

    Measured by a 26-item Self-efficacy Measure for Sleep Apnea, with 3 subscales: the perceived risk of sleep apnea, PAP outcome expectations, and treatment self-efficacy. Scores of subscale ranged from 1 to 4. Higher scores indicate greater perceived self-efficacy, greater perceived response efficacy, and higher perceived susceptibility.

    Time frame: Baseline and 4 months

  5. Dietary habits

    Measured by a 10-item outcome-based dietary practice questionnaire. Scores ranged from 1 to 5. The higher scores indicate the worse dietary practice.

    Time frame: Baseline and 4 months

  6. Physical activity level

    Measured by an 4-item International Physical Assessment Questionnaire - short version. Ranged from 0 to 24 hours per day. The higher scores represent higher physical activity level.

    Time frame: Baseline and 4 months

  7. Daytime sleepiness

    Measured by an 8-item Epworth Sleepiness Scale. Scores ranged from 0 to 24. Higher scores indicate more sleepy during daytime.

    Time frame: Baseline and 4 months

  8. Sleep quality

    Measured by a 7-item Insomnia Severity Index. Higher scores indicate poorer sleep quality

    Time frame: Baseline and 4 months

  9. Quality of life

    Measured by a 10-item Functional Outcomes of Sleep Questionnaire. Total scores ranged from 5 to 20. The higher scores indicate better functional status.

    Time frame: Baseline and 4 months

  10. Waist circumference

    Measured by measuring tape

    Time frame: Baseline and 4 months

  11. Body mass index

    Calculated by height and weight

    Time frame: Baseline and 4 months

  12. Body fat composition

    Measured by bioimpedance scale

    Time frame: Baseline and 4 months

  13. Severity of sleep apnoea

    Measured by a Home-sleep test

    Time frame: Baseline and 4 months

  14. Technology acceptance

    Measured by a 7-item modified Technology acceptance model questionnaire. Ranged 1 to 7 for each item. Higher scores indicate better acceptance.

    Time frame: 4 months

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — It has not been mentioned during the IRB application

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07494292
Lead sponsor
Hong Kong Metropolitan University
Collaborators
Queen Mary Hospital, Hong Kong
Responsible party
Professor Agnes LAI Yuen Kwan (Professor, Hong Kong Metropolitan University) — Principal investigator
First posted
Mar 27, 2026
Start date
Aug 3, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Yuen Kwan Agnes Lai, PhD
Contact
ayklai@hkmu.edu.hk
(852)3970-2917
On Chu George Cheung, MPhil
Contact
occheung@hkmu.edu.hk
(852)3970-2933
Yuen Kwan Agnes Lai, PhD
principal investigator · Hong Kong Metropolitan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion